The ambulatory surgery center company discussed its plans for improving its sluggish performance on today's third-quarter conference call, after posting a Q3 loss. A new purchasing agreement should help with cost management, while a heavier focus on physician recruitment and service line development is aimed at growing same-store revenues.
Nov 13, 2009 2:36 PM
SmartMoney's Jack Hough has culled through the numbers to unearth some stocks that provide solid growth at a nice price. Among his finds is Nashville-based AmSurg, which from 2005 to 2008 grew its top line by 64 percent and its operating earnings by 57 percent. Today, its shares (Ticker: AMSG) are up about 2 percent, in line with the broader market.
Nov 5, 2009 12:47 PM
Group interested in Nashville health care innovations, relationships with local industry leaders
Oct 23, 2009 12:15 PM
'Clarity about lack of clarity' on health reform helps acquisition pipeline
Oct 22, 2009 7:26 PM
Expense growth outstrips revenues at surgery center operator
Aug 13, 2009 7:36 AM
Healthways lands its first WholeHealth contract, AmSurg taps a new chairman
Jul 23, 2009 3:32 PM
Ambulatory surgery center operator AmSurg, which yesterday received an upgrade to 'Buy' from TheStreet.com Ratings, this morning was downgraded to 'Neutral' by Whit Mayo from Robert W. Baird
A Robert W. Baird analyst downgraded outpatient surgery center operator AmSurg Corp. Tuesday, citing a lack of upcoming catalysts and the likelihood the stock will remain flat. Baird analyst Whit Mayo lowered his rating to "Neutral" from "Outperform" but lowered his price target to $23 from $24, saying the share value has returned to a more reasonable level. "Thus, outside of a re-acceleration in earnings, we see few significant catalysts and expect the stock to trade sideways," he wrote in a note to investors.
Jul 7, 2009 10:10 AM
TheStreet.com Ratings announced early this morning that it has upgraded surgery center operator AmSurg to "Buy"
The numbers: Fiscal first-quarter revenue rose 12% to $163 million as net income climbed 7.8% to $13 million and earnings per share ascended 8.1% to 40 cents, extending a growth streak to nine quarters. The cash balance is ample with $31 million of reserves. The debt-to-equity ratio is low at 0.6. The net margin is wide at 7.7% but has shed 30 basis points since last year's first quarter. The stock: Amsurg is down 10% in 2009, trading at a price-to-earnings ratio of about 13. The company has a market capitalization of $670 million.
Jul 6, 2009 11:39 AM